On September 4, 2026, XPENG-W (09868.HK) traded firmly in the afternoon session. As of 15:15, the stock traded at HK$43.54, up 1.73%.
September 4, 2026—The chip theme continued to come under pressure, with Hua Hong Grace (01347.HK) slumping sharply. As of 13:40, the stock was quoted at HK$109.100, down 8.93%.
on September 4, 2026, the robotics theme weakened amid volatility, while Midea Group (00300.HK) strengthened against the trend. As of 13:26, the company's quote was HK$101.000, up 0.50%.
On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has accepted the marketing application for Zhuotuoqibai injection (SHR-1819), an IL-4Rα-targeting antibody independently developed by its subsidiary Guangdong Hengrui, for moderate to severe atopic dermatitis in adults; the Phase III study (652 patients) met both co-primary efficacy endpoints with results significantly superior to placebo.
On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has accepted the marketing application for HRS-7535 tablets, an oral small-molecule GLP-1 receptor agonist developed by its subsidiary Shandong Shengdi, for long-term weight management in adults (obesity or overweight with comorbidities); the pivotal Phase III study showed an average weight reduction of up to 11.1% in the 180mg group at week 50.
On 3 September 2026, SIMCERE PHARMA (02096.HK) announced that Yimule (Kulaiweibai injection), a domestic Class 1 innovative biologic developed in strategic cooperation with Ruiyang, has been approved by the NMPA for marketing in China, for the prevention of RSV-associated lower respiratory tract infection in neonates and infants; Phase III data showed 85.32% protective efficacy against RSV-associated lower respiratory tract infection requiring medical intervention and 83.27% against RSV-associated hospitalisation at 150 days after administration.
On 3 September 2026, CMS (00867.HK) announced that its subsidiary Deme Medical's ruxolitinib cream Baicor has been approved by the NMPA for mild-to-moderate atopic dermatitis (registration certificate received on 3 September), marking its second indication after vitiligo.
On September 3, 2026, the three major Hong Kong indices opened higher but closed lower: the Hang Seng Index fell 0.39%, the Hang Seng TECH Index fell 1.08%, and the Hang Seng China Enterprises Index fell 0.77%. The Hang Seng Index's full-day turnover was HK$199.4 billion, and southbound funds recorded a net inflow of HK$3.395 billion. AI concept stocks showed a divergent performance on the day, with the intelligent-driving direction broadly strengthening, while the AI chip and large-model directions were mostly under pressure.
On September 3, 2026, BIDU-W (09888.HK) drifted lower in the afternoon. As of 15:27, the stock traded at HK$91.50, down 0.92%.
NewTimeSpace (newtimespace.com) News, on September 3, 2026, the chip theme weakened amid volatility while ASMPT (00522.HK) strengthened against the trend. As of 13:46, the stock was quoted at HKD 161.600, up 2.67%.
NewTimeSpace (newtimespace.com) News, on September 3, 2026, the robot theme rose amid volatility while XIAOMI-W (01810.HK) weakened. As of 13:33, the stock was quoted at HKD 27.320, down 2.64%.
On 2 September 2026, CH BIOTECH SER (08037.HK) announced that its Penbo (Hainan) BNCT Hospital has entered into a framework cooperation agreement with Oncare Cancer Centre of Hong Kong to establish cross-border oncology cooperation under an "overseas assessment, domestic treatment, overseas follow-up" model; the Hospital operates in the Boao Lecheng pilot zone, and the first 10 head and neck cancer patients achieved an overall response rate of 80%.
On 3 September 2026, AKESO (09926.HK) announced that the OS interim analysis of the HARMONi-2 study of ivonescimab (PD-1/VEGF) as first-line treatment for PD-L1-positive NSCLC met the key secondary OS endpoint with statistical significance and clinical benefit; the study had previously met its primary PFS endpoint (median PFS 11.14 vs 5.82 months, HR=0.51).
On 3 September 2026, CUTIA-B (02487.HK) announced that the BLA for CU-20101 (botulinum toxin type A for injection) has been accepted by the NMPA for the indication of improving moderate to severe glabellar lines; the product's manufacturing process will not use animal-derived materials or human serum albumin, aiming to eliminate the risks of TSE infection and allergic reactions.
On September 2, 2026, the three major Hong Kong indices trended lower amid volatility. The Hang Seng Index edged down 0.07%, the Hang Seng TECH Index fell 0.74%, and the Hang Seng China Enterprises Index edged down 0.15%.AI concept stocks diverged in performance on the day — large models were mixed, while the AI chip sector and the intelligent driving direction came under collective pressure.
On 2 September 2026, PEGBIO CO-B (02565.HK) announced a material transfer agreement with Korean biotech SN BioScience to apply its SNA long-acting delivery platform to three metabolic disease peptide candidates including APGP6.
